In this episode of Derms and Conditions, host James Q. Del Rosso, DO, sits down with Cheri Frey, MD, residency program director and director of cosmetic dermatology at Howard University, to discuss the clinical nuances of facial hyperpigmentation, with a special focus on melasma and the emerging role of Thiamidol.

 Dr Frey begins by breaking down how she categorizes facial hyperpigmentation that isn't tied to a structural lesion. She explains how the distribution, hue, and depth of pigment—epidermal, dermal, or mixed—guide diagnosis and treatment. They revisit traditional therapies like hydroquinone and oral tranexamic acid, highlighting their ongoing roles in management, while noting concerns around cytotoxicity, ochronosis, and overuse.

 The conversation then turns to Thiamidol, a novel topical agent recently introduced in the US as a potent and selective human tyrosinase inhibitor, unlike many legacy agents developed using mushroom tyrosinase models. Dr Frey shares data showing the superiority of Thiamidol over 2% hydroquinone and comparable efficacy to 4%, with excellent tolerability and quality-of-life benefits. Clinical applications span melasma, acne-induced postinflammatory hyperpigmentation, solar lentigines, and laser-associated hyperpigmentation.

 Dr Frey also discusses an exciting new study where Thiamidol replaced hydroquinone in triple-combination creams, yielding similar efficacy with improved tolerability, offering new options for patients seeking long-term, safer treatments.

 Tune in to the full episode to hear how Dr Frey approaches hyperpigmentation with precision and pragmatism, and how Thiamidol may be poised to reshape the treatment landscape.